![Page 1: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/1.jpg)
Insert Cover Image using Slide Master ViewDo not distort
Stem Cell Research IndiaStem Cell Research – India
July 2012
![Page 2: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/2.jpg)
Executive Summary
Market
• The Stem Cell Therapy market in India was valued at INR x1 units in 20‐‐ which is expected to reach INR x2 units approximately by 20‐‐• The Stem Cell Banking Market was worth INR y1 units in 20‐‐ and is expected to reach INR y2units in 20‐‐
• India is projected to see a rise in number of stem cell bank and stem cell depositors in near
Drivers: Challenges:
• India is projected to see a rise in number of stem cell bank and stem cell depositors in near future
•Favorable Regulatory Environment•High Cost of Therapy
Drivers & Challenges
•High Patient Population•Application in Drug Development•Increasing Awareness•Growing Medical Tourism•Increasing Health Expenditure
•High Cost of Therapy• Capital intensive nature of research is decelerating the market
• ‘Development Costs’ of Stem Cell resulting in slow progress of the market
Trends
•Increasing Health Expenditure
•Increasing partnerships•Increasing investments
• Efforts to increase awareness in stem cell• Easy financing opportunities in stem cell banking
Competition
Major Players
Stem Cell Banks Company A, Company B, Company C, Company D, Company E, Company F
Organization A Organization B Organization C Organization D
STEM CELL RESEARCH MARKET IN INDIA 2012.PPT 2
Stem Cell Research OrganizationsOrganization A, Organization B, Organization C, Organization D, Organization E, Organization F, Organization G, Organization H
![Page 3: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/3.jpg)
•Introduction•Market Overview•Drivers & Challenges•Value ChainM k t T d•Market Trends•Potential Stem Cell Sources•Competition•Competition Stem Cell Banks Research OrganizationsResearch Organizations
•Recent Developments•Strategic Recommendations
STEM CELL RESEARCH MARKET IN INDIA 2012.PPT 3
g•Appendix
![Page 4: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/4.jpg)
Stem cell banking and therapeutic application are the two key area of concern which are bridged by stem cell research
Stem Cell can be the solution to a myriad of diseases like Parkinson's disease, amyotrophic lateral sclerosis, spinal cord injury, burns, heart disease, diabetes and arthritis and also for neurological problems like autism and cerebral
palsy and is also becoming an important tool for testing potential drug toxicity
• It is an emerging therapy wherein a damaged tissue • It is a concept of preserving the stem cells for specific future therapeutic uses
Stem Cell Therapy Stem Cell Banking
that cannot heal itself is repaired by the use of stem cell• Stem cells are the unspecialized blood cell that has the capacity to replicate and produce its own blood cells, platelets, red and white blood cells
• The “Cord Blood” is a rich source of stem cells and a
• The extraction of cord blood stem cells take about 10–15 minutes and is applicable to both normal and caesarean deliveries
• The cells can be cryo‐frozen and kept stored for decades in liquid nitrogen• The Cord Blood is a rich source of stem cells and a
critical input for such surgical treatmentsliquid nitrogen
• Cord blood is more like a ‘biological future health insurance’ for the newborn baby and its future offspring’s and siblings
•Use not restricted•No remuneration collected•Usage subject to availability
Public Banks
•For use of family only•Facility paid for by family•Availability guaranteed
Private Banks
STEM CELL RESEARCH MARKET IN INDIA 2012.PPT 4
The benefits of stem cell is manifold as the cell’s usage is not just restricted to the child but siblings or family members can use the cells if required, after a tissue matching is done
![Page 5: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/5.jpg)
Stem cell therapy market is poised to grow at a very high rate due to increasing therapeutic applications
• The Stem Cell Therapy market in India was valued atINR x1 units in 20‐‐
Stem Cell Therapy Market – Overview Market Size and Growth
80
INR units
• The market is expected to reach INR x6 unitsapproximately by 20‐‐, growing at a CAGR of X% forthis time period
• The stem cell research is a key factor that propels thetherapeutic market 20
40
60 X% x6x5
x4x3
x2x1x0
therapeutic market
• Almost m stem cell transplants are carried out inIndia annually that is growing gradually
0
20
20‐‐e20‐‐e20‐‐e20‐‐e20‐‐e20‐‐20‐‐
Stem Cell Banking Market Overview Market Size and Growth
• The Stem Cell Banking Market was worth INR y1units in 20‐‐ and is expected to reach INR y6 units in20‐‐
h ll b k k d h b
Stem Cell Banking Market – Overview
8
10
INR units
y6
Market Size and Growth
• The stem cell banking market is expected to exhibit aCAGR of Y% between 20‐‐ and 20‐‐
• Stem cell banking that was unheard of a few yearsback but has become popular in the recent past as aless traumatic alternative to treat neurological 2
4
6
8Y% y5
y4y3
y2y1y0
STEM CELL RESEARCH MARKET IN INDIA 2012.PPT 5
less traumatic alternative to treat neurologicaldiseases and as guarantee for the entire familyagainst several other diseases
020‐‐e20‐‐e20‐‐e20‐‐e20‐‐e20‐‐20‐‐
![Page 6: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/6.jpg)
Drivers & Challenges – Summary
iDrivers
Favorable Regulatory EnvironmentChallenges
High Patient Population
Application in Drug Development
High Cost of Therapy
Capital Intensive Market
Increasing Awareness
Growing Medical Tourism
High Development Cost
Increasing R&D Expenditure
STEM CELL RESEARCH MARKET IN INDIA 2012.PPT 6
![Page 7: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/7.jpg)
Trends – Summary
Easy financing opportunities in stem cell banking Increasing Partnerships
Key Trends
Efforts to increase awareness in stem cell
Increasing Investments
STEM CELL RESEARCH MARKET IN INDIA 2012.PPT 7
![Page 8: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/8.jpg)
Private: Foreign Company – Company A (1/3)
Company Information Offices and Centres – India
Corporate Address
Company A
Street A
City BCity B
State C
Tel No. +91 124 7239
Fax No +91 124 4734111
City B
P d t d S i
Fax No. +91 124 4734111
Website www.CompanyAcom
Year of Incorporation 2005
Key People
Products and Services
Category Products/Services
Stem cell banking Engages in collection, isolation and storage of cord blood stem cells
Head Office
Name Designation
Person A Chairman
Person B Managing Director
Person C CEO
STEM CELL RESEARCH MARKET IN INDIA 2012.PPT 8
Person C CEO
![Page 9: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/9.jpg)
i i l S h K i
Private: Foreign Company – Company A (2/3)
Financial Snapshot Key Ratios
Particulars y‐o‐y change (2011‐10)
2011 2010 2009 2008
Profitability RatiosOperating Margin
Net Profit/LossTotal Income
INR units
‐20
INR units
250Net MarginProfit Before Tax MarginReturn on EquityReturn on Capital EmployedReturn on Working CapitalReturn on Assets
20
‐40
‐60
250
200
150
100
50
dR4c
R3b
R2
a
Return on Fixed Assets
Cost RatiosOperating costs (% of Sales)Administration costs (% of Sales)
Interest costs (% of Sales)Financial Summary
‐80
50
020‐‐20‐‐20‐‐20‐‐
R1
Interest costs (% of Sales)
Liquidity RatiosCurrent RatioCash Ratio
Leverage RatiosDebt to Equity Ratio
b i l i
• The company incurred a net loss of INR d units in FY 20‐‐, as compared to net loss of INR c units in FY 20‐‐
• The company reported total income of INR R4 units in FY 20‐‐, registering an increase of m% over FY 20‐‐
Debt to Capital RatioInterest Coverage Ratio
Efficiency RatiosFixed Asset TurnoverAsset TurnoverCurrent Asset Turnover
• The company earned an operating margin of f% in FY 20‐‐, an increase of g percentage points over FY 20‐‐
• The company reported debt to equity ratio of d in FY 20‐‐, a decrease of h% over FY 20‐‐
STEM CELL RESEARCH MARKET IN INDIA 2012.PPT 9
Working Capital TurnoverCapital Employed Turnover
Improved Decline
![Page 10: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/10.jpg)
Private: Foreign Company – Company A (3/3)
Business Highlights
Description News
Overview • It was formed as a joint venture between Company A and Company B
Stem Cell Banking • It provides collection facility from all major cities in India
Recognitions• The company was awarded the most prestigious American Association of Blood Banks (AABB) Accreditation
STEM CELL RESEARCH MARKET IN INDIA 2012.PPT 10
![Page 11: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/11.jpg)
Appendix
Ratio Calculations
Operating Margin (Operating Income/Revenues)*100
Ratio Calculations
Current RatioCurrent Assets / Current Liabilities
Net Margin (Net Profit / Revenues) *100
Profit Before Tax Margin (Income Before Tax / Revenues *100
(N I / Sh h ld
Cash Ratio{(Cash & Bank Balance + Marketable Securities) / Current Liabilities)}
Debt to Equity Total Liabilities / Shareholders E it
Return on Equity (ROE) (Net Income / Shareholders Equity)*100
Return on Capital (ROCE) EBIT / (Total Assets – Current Liabilities)*100
(N I / W ki C i l)
q yEquity
Debt to Capital Ratio{Total Debt / (Shareholders Equity + Total Debt)}
Interest Coverage Ratio EBIT / Interest Expense
Return on Working Capital (Net Income / Working Capital) *100
Return on Assets (Net Income / Total Assets)*100
Return on Fixed Assets (Net Income / Fixed Assets) *100
Fixed Asset Turnover Sales / Fixed Assets
Asset Turnover Sales / Total Assets
Operating Costs (% of Sales) (Operating Expenses / Sales) *100
Administration Costs (% of Sales)
(Administrative Expenses / Sales) *100
Current Asset Turnover Sales / Current Assets
Working Capital Turnover Sales / Working Capital
/
STEM CELL RESEARCH MARKET IN INDIA 2012.PPT 11
Interest Costs (% of Sales) (Interest Expenses / Sales) *100 Capital Employed Turnover Sales / Shareholders Equity
![Page 12: Market Research Report : Stem Cell Research Marklet in India 2012](https://reader033.vdocuments.net/reader033/viewer/2022052821/55490f88b4c90565458bd209/html5/thumbnails/12.jpg)
Thank you for the attentionThe Stem Cell Research Market – India report is part of Research on India’s Healthcare Series.For more detailed information or customized research requirements please contact:
Phone: +91 33 4064 6214Phone: 91 33 4064 6214E‐Mail: [email protected]
Follow us on:
About NetscribesNetscribes is a knowledge‐consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment & g g f g p y p p fbusiness research, business & corporate intelligence, content‐management services, and knowledge‐software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes is a one‐stop shop designed to fulfil clients’ profitability and growth objectives.
Disclaimer: This report is published for general information only Although high standards have been used in the preparation “Netscribes” is
STEM CELL RESEARCH MARKET IN INDIA 2012.PPT 12
Disclaimer: This report is published for general information only. Although high standards have been used in the preparation, Netscribes is not responsible for any loss or damage arising from use of this document. This document is the sole property of Netscribes and prior permission is required for guidelines on reproduction.